Last year, NIA's President collaborated with Inc.com to interview Dr. Rick Doblin the founder and executive director of the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (MAPS) about their Phase 3 FDA trials of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD): click here to watch the video.
On September 27th, NIA announced Numinus Wellness (TSXV: NUMI) at $0.285 per share as its #1 favorite psychedelic stock suggestion and one of its Top 5 favorite overall stock suggestions.
This week, NUMI announced a collaboration agreement with MAPS that will seek approval to deliver MDMA-assisted psychotherapy for PTSD through a single-arm, open-label, compassionate access trial in Canada. This compassionate access trial, if approved, will be conducted at NUMI's Vancouver clinic, providing MDMA-assisted psychotherapy to an initial 20 individuals experiencing PTSD and collecting outcome and safety data for Health Canada. NUMI's physicians, therapists and staff will be trained to deliver the treatment under MAPS’ clinically-tested PTSD treatment protocol prior to approval by Health Canada.
NUMI finished this week at $0.78 per share, its highest weekly closing price since NIA's initial suggestion at $0.285 per share.
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from NUMI of USD$30,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.